Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 12/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.42 |
| ▸ | PTPRA | P18433 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPRG | P23470 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6803115 | 0.85 | KCNA5 (0.41) | PTGER2KCNA5MEN1KMT2A | |
| SCHEMBL6803479 | 0.83 | PTPRB (0.45) | PTPRBPTPN11PTPN1PTPN2PTPRA | |
| SCHEMBL6807936 | 0.82 | MMP1 (0.42) | PTPN1KCNH2KMT2A | |
| SCHEMBL6796826 | 0.81 | PTPRB (0.45) | PTPRBPTPN11MEN1KMT2A | |
| SCHEMBL7063146 | 0.72 | STAT5B (0.47) | MEN1KMT2A | |
| SCHEMBL4880111 | 0.71 | CA12 (0.45) | MEN1KMT2A | |
| SCHEMBL6802181 | 0.68 | PTPRB (0.60) | PTPRBPTPN1PTPN2PTPRA | |
| SCHEMBL6807428 | 0.68 | PTGER2 (0.41) | PTGER2 | |
| SCHEMBL5280924 | 0.67 | LTB4R (0.51) | KCNH2 | |
| SCHEMBL6795785 | 0.67 | PTPRB (0.51) | PTPRBPTPN11PTPN1PTPN2PTPRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | claimed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | claimed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167183-A1 | Phenethylamino sulfamic acids | PTPRM, PTPRS, PTPRE | PTPRB 13/4885PTPN11 31/4885PTPN1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.